These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3753658)

  • 1. Reversible mechlorethamine-associated hearing loss in a patient with Hodgkin's disease.
    Segal GM; Duckert LG
    Cancer; 1986 Mar; 57(6):1089-91. PubMed ID: 3753658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
    Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
    J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
    Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
    Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MOPP, ABVD, or both to treat Hodgkin's disease.
    Aisenberg AC
    N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
    [No Abstract]   [Full Text] [Related]  

  • 6. [Myocardial infarct in a patient with Hodgkin's disease treated with cyclic polychemotherapy].
    Matusewicz W; Drzewoski J; Robak T; Krykowski E
    Kardiol Pol; 1983; 26(7):591-4. PubMed ID: 6689036
    [No Abstract]   [Full Text] [Related]  

  • 7. [CVP or C-MOPP combination chemotherapy in the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma (intermediate grade of working formulation)].
    Sampi K; Honda T; Hattori M
    Rinsho Ketsueki; 1984 Feb; 25(2):164-8. PubMed ID: 6547984
    [No Abstract]   [Full Text] [Related]  

  • 8. [Acute myeloid leukemia after treatment of Hodgkin's disease].
    Carneiro PC; Pereira ED; Mitteldorf CS; Martinez GA; Beitler B; Pozzi DH
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(2):87-90. PubMed ID: 2616992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
    Canellos GP
    Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055
    [No Abstract]   [Full Text] [Related]  

  • 10. [MOPP therapy of Hodgkin's disease previously treated with MOPP].
    Frau A; Montalar J
    Med Clin (Barc); 1985 May; 84(19):801. PubMed ID: 3839875
    [No Abstract]   [Full Text] [Related]  

  • 11. [Late results of the treatment of advanced Hodgkin's disease by the MOPP/COPP programs (chlormethine or cyclophosphamide, vincristine, procarbazine and prednisone)].
    Błasińska-Morawiec M; Płuzańska A; Krykowski E; Robak T; Mrówka I
    Pol Arch Med Wewn; 1991 Oct; 86(4):274-80. PubMed ID: 1813880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy.
    Diehl LF; Perry DJ; Terebelo H; Baldwin PE; Hurwitz M; Kimball DB; Dorn RV
    Cancer Treat Rep; 1983 Sep; 67(9):827-9. PubMed ID: 6883360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty years of MOPP therapy for Hodgkin's disease.
    Longo DL; Young RC; Wesley M; Hubbard SM; Duffey PL; Jaffe ES; DeVita VT
    J Clin Oncol; 1986 Sep; 4(9):1295-306. PubMed ID: 3528400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of sternum and rib in a patient treated for Hodgkin's disease.
    Blijham GH; Vermeulen A; Mendes de Leon DE
    Cancer; 1985 Nov; 56(9):2292-4. PubMed ID: 3840407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP.
    Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D
    Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy.
    da Cunha MF; Meistrich ML; Fuller LM; Cundiff JH; Hagemeister FB; Velasquez WS; McLaughlin P; Riggs SA; Cabanillas FF; Salvador PG
    J Clin Oncol; 1984 Jun; 2(6):571-7. PubMed ID: 6547167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?
    Dodwell DJ; de Campos ES; Radford JA
    Drugs; 1992 Jul; 44(1):1-8. PubMed ID: 1379906
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.